Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden

Clinical Breast Cancer

Volumn 7, Issue 6, 2007, Pages 34-42

  Cristofanilli, Massimo ^a   Broglio, Kristine R ^a   Guarneri, Valentina ^a   Jackson, Summer ^a   Fritsche, Herbert A ^a   Islam, Rabiul ^a   Dawood, Shaheenah ^a   Reuben, James M ^a   Kau, Shu Wan ^a   Lara, Juanita M ^a   Krishnamurthy, Savitri ^a   Ueno, Naoto T ^a   Hortobagyi, Gabriel N ^a   Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CA27 29; Cancer antigen; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TRASTUZUMAB; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CELL ISOLATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; TUMOR CELL; TUMOR VOLUME; VISCERAL METASTASIS;

EID: 33947286218     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.004     Document Type: Article

References (36)

1. Ellis M, Hayes DF, Lippman ME. Treatment of Metastatic Disease. In: Harris J, Lippman M, Morrow M, et al, eds. Diseases of the Breast. 2nd ed. Philadelphia, PA: Lippincott-Raven; 2000:749-799.
2. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197-2205.
3. Nieto Y, Cagnoni PJ, Shpall EJ, et al. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 1999; 5:1731-1737.
4. Rivera E, Holmes FA, Buzdar AU, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer who have no evidence of disease. Breast J 2002; 8:2-9.
5. Clark GM. Prognostic and predictive factors. In: Harris J, Lippman M, Morrow M, et al, eds. Diseases of the Breast. New York: Lippincott-Raven; 1996:461-485.
6. Swenerton KD, Legha SS, Smith L, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39:1552-1562.
7. Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1:776-786.
8. Montemurro F, Rondón G, Munsell M, et al. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow TR 2003; 9:330-340.
9. Kurebayashi J, Yamamoto Y, Tanaka K, et al. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Breast Cancer 2003; 10:38-44.
10. Einarsson R, Lindman H, Bergh J. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients. Anticancer Res 2000; 20:5089-5093.
11. Tampellmi M, Berutti A, Gerbino A, et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75:698-702.
12. De La Lande B, Hacene K, Floiras JL, et al. Prognostic value of CA 15-3 kinetics for metastatic breast cancer. Int J Biol Marker 2002; 17:231-238.
13. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of estrogen receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10:1284-1291.
14. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer (MBC): an Intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
15. Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 1999; 85:104-111.
16. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-1878.
17. Cristofanilli M, Budd GT, Ellis M, et al. Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791.
18. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23:1420-1430.
19. Sørlie T, Tibshirani R, Parker J, et al Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-8423.
20. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-5374.
21. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002; 25:104-110.
22. Terstappen LW, Rao C, Gross S, et al. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 2000; 17:573-578.
23. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: a simulation study. Stat Med 1999; 18:3075-3088
24. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004; 9:617-632.
25. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
26. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-5685.
27. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-357.
28. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
29. Müller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11:3678-3685.
30. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10:8152-8162.
31. Li Y, Rosen JM. Stem/progenitor cells in mouse mammary gland development and breast cancer. J Mammary Gland Biol 2005; 10:17-24.
32. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005; 7:86-95.
33. Ponti D, Costa A, Zaffaroni N, et al. Isolation and n vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65:5506-5511.
34. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, et al. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003; 33:3242-3254.
35. Mensdorff-Pouilly S, Kinarsky L, Engelmann K, et al. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 2005; 15:735-746.
36. Huflejt M.E., Cristofanilli M, Shaw L, et al. Detection of neoplasia-specific clusters of anti-glycan antibodies in sera of breast cancer patients using a novel glycan array. Am Assoc Cancer Res 2005; 46:1313 (Abstract #8115).